GlassScriptPhysician profile
Jeffrey Carlson
NPI 1750642849
$2,034.31
in general payments reported to CMS, 2019-2025
26 companies · $566 in 2025
The $566 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.00 · 2020: $233 · 2021: $400 · 2022: $74.66 · 2023: $83.01 · 2024: $651 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $728.72 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $189.48 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $163.00 | 2020-2025 | Taltz, Jardiance, Zepbound |
| Dexcom, INC. | $150.66 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $95.35 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.87 | 2020-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $79.07 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
| Daiichi Sankyo INC. | $69.15 | 2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.88 | 2021 | |
| Novo Nordisk INC | $58.17 | 2025 | Wegovy, Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $37.21 | 2020-2021 | |
| Exact Sciences Corporation | $31.96 | 2023-2024 | Cologuard Collection Kit |
| Bioxcel Therapeutics, INC. | $24.68 | 2023 | Igalmi |
| Amarin Pharma, INC. | $24.52 | 2021 | |
| Allergan, INC. | $24.43 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $22.62 | 2025 | Tlando |
| Ultragenyx Pharmaceutical INC. | $22.17 | 2024 | Crysvita |
| Astellas Pharma US INC | $21.70 | 2025 | Veozah |
| Atricure, INC. | $21.18 | 2021 | |
| Abbott Laboratories | $20.17 | 2024 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $20.02 | 2025 | Zenpep |
| Sumitomo Pharma America, INC. | $19.74 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $18.86 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $15.36 | 2021 | |
| Esperion Therapeutics, INC. | $15.35 | 2020 | |
| Sanofi Pasteur INC. | $13.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.